key: cord-0757684-7c0hicl9
authors: Raturi, Manish; Kusum, Anuradha; Kala, Mansi; Mittal, Garima; Sharma, Anita; Bansal, Naveen
title: Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants
date: 2021-05-07
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.05.003
sha: d6244aaf821c0e7439195e7e192c7cb1897a2cf5
doc_id: 757684
cord_uid: 7c0hicl9

The only effective way to provide individuals with herd immunity against the novel coronavirus [SARS-CoV-2] is to administer an effective vaccine that will help check the current pandemic status. In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, Covishield (live vaccine, Oxford AstraZeneca, United Kingdom being manufactured by the Serum Institute of India), Covaxin (inactivated vaccine, Bharat Biotech, India) and Sputnik V (live vaccine, Gamaleya, Russia). However, there is a rising need for the efficacy of the vaccines to be proven against the “SARS-CoV-2 viral variants.” Also, human plasma is polyclonal in nature with an inherent propensity to identify multiple epitopes of either an antigen or pathogen. With this context in mind, the researchers hypothesize that using COVID-19 convalescent plasma [CCP] harvested from the locally recovered individuals [i.e. potential CCP donors] may be particularly beneficial in combating not only the founder SARS-CoV-2 virus but also the geographically confined SARS-CoV-2 variants among the regionally affected COVID-19 patients.

. Furthermore, currently, in the absence of any definite cure, the most effective way to combat the COVID-19 pandemic is to develop herd immunity in the population through a safe and effective vaccine [2] . All the viruses, including SARS-CoV-2, evolve with time. In fact, when a virus replicates or makes copies of itself, it sometimes changes a little bit, which is a normal phenomenon. These changes are termed "mutations". A virus with one or more of these novel mutations is hence referred to being a "variant" of the founder strains. Likewise, SARS-CoV-2 variants have emerged [3] [4] [5] and elude the antibodies elicited by the ancestral or founder SARS-CoV-2 strains. Additionally, with the multiple genomic sequence data of the nCoV already available since the clinical trials to produce vaccines against this nCoV [6] . In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, 

On scientists believe that the vaccines that are currently in development and a few that have been approved should be able to protect against the variants because these vaccines elicit a fairly broad immune response, in the form of a host of antibodies and cell-mediated immune responses [9] .

As a potent anti-viral, CCP can help neutralize the nCoV [1] . In fact administration of monoclonal Ab combinations (oligoclonal "cocktails") can revoke the emergence of resistant viruses, as has already been demonstrated for SARS-CoV-2 mAbs [10] . CCP on the other hand is polyclonal in nature and contains antibodies with paratopes against various epitopes of a pathogen or protein giving it a chance to neutralize a wide variety of pathogens. Further, individuals who recover from variant COVID-19 are likely to generate CCP capable of neutralizing SARS-CoV-2 variants [11] . Hence, variant CCP from a locally determined region could help become a potential antidote for variant SARS-CoV-2 of multiple specificities in a geographically defined area. Therefore, as SARS-CoV-2 variant strains spread in human populations, the locally harvested CCP units will be especially efficacious for the regional patients or carriers harbouring these SARS-CoV-2 variants.

As we enter the second quarter of 2021, the world is still in a situation where new evidence becomes available every day and we're learning new things. But at the same time, we have to act in real-time to protect ourselves. The only effective way to check the spread at the source remains the key. Current measures to reduce transmission include frequent hand washing, wearing a mask, respiratory etiquette, physical distancing, good ventilation and avoiding crowded places or closed settings. All these measures will continue to work against emerging variants by reducing the viral transmission and hence also reducing the opportunities for the virus to mutate. Scaling up the manufacturing of vaccines and rolling out vaccination program as early and widely as possible will also be a critical way of helping to protect people from the risk of new variants. However, priority should be given to vaccinating high-risk groups such as the elderly or people with co-morbidities everywhere to maximize global protection against the risk of acquiring the infection. We may rightly say that "I am safe only if everyone is safe".

Detection of novel variants [3] [4] [5] has emphasized the need for sequence-based strain surveillance, to promptly detect mutations to prevent their spread. WHO further advises countries, where feasible, to increase the routine, systematic sequencing of SARS-CoV-2 viruses to better understand the SARS-CoV-2 transmission and to monitor for the emergence of variants. This sequence data should then be shared internationally through community accessible databases. However, in countries without sequencing capacity, CCP recovered and harvested from a local seroconverted person could help fight against the geographically determined novel variants provided CCP administration is initiated before the development of the cytokine storm in the sufferer.

To sum up, "vaccination for all" is a desirable need of the hour. In fact, modifying COVID-19 vaccines would probably be the most straightforward way of dealing with SARS-CoV-2 variants. Until this happens, the use of universal infection prevention strategies in conjunction with building the local CCP donor registry through voluntary camps and having a sufficient inventory of AB-type harvested CCP in a regional blood centre might help address the fight against the SARS-CoV-2 variants.

Funding and resources: None.

The authors declare that they have no competing interests.

Current Perspectives of convalescent plasma therapy in COVID-19

Herd Immunity: Understanding COVID-19

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus Preliminary findings

Genomic Surveillance of SARS-CoV-2: Distribution of Clades in the Republic of Korea in 2020

The blood supply management amid the COVID-19 outbreak

COVID-19 vaccination in the Indian blood donors: Adjudging the impact on the deferral period

Coronavirus disease (COVID-19)

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities